Device Trial Radar · NCT00814840
Efficiency Study of Triple-Site Cardiac Resynchronization in Patients With Heart Failure
Last checked: Nov 19, 2026Latest source record: Apr 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Feb 2008
Primary completion
Jul 2010
Study completion Jan 2015
Sponsor
- Lead sponsor
- Silesian Centre for Heart DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 25, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficiency of permanent biventricular pacing using three ventricular leads in terms of reduction in adverse cardiac events rates, improvement in cardiac capacity and patients' functional status in subjects with congestive heart failure and a physiologic (sinus) rhythm.
Conditions
- Congestive Heart Failure
- Heart Disease
Interventions
Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leadsDevice
Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
Triple-site cardiac resynchronizationDevice
Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined end-point of alive status, freedom from hospitalization for HF or heart transplantation, relative ≥10% increase in LV ejection fraction, ≥10% in VO2max and ≥10% in 6MWD.Time frame: six months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Department of Cardiology, Silesian Medical University, Silesian Center for Heart Diseases
Zabrze, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.